| Identification | Back Directory | [Name]
bimekizumab | [CAS]
1418205-77-2 | [Synonyms]
bimekizumab
Anti-IL-17-mAb-UCB
Anti-IL-17-monoclonal-antibody-UCB
Research Grade Bimekizumab(DHH28803)
Anti-interleukin-17-monoclonal-antibody-UCB |
| Hazard Information | Back Directory | [Uses]
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1]. | [IC 50]
IL-17A; IL-17F | [References]
[1] Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306. DOI:10.1136/rmdopen-2020-001306 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|